It was excluded from future repurposed drug studies specifically because the dose from the few studies that have not been retracted about it is so uncertain.
Most studies and meta analysis since May show that it works about as well as a placebo.
In our Cochrane Review, we assessed the identical set of trials. However, only 4 of the 15 trials included in Bryant’s meta-analysis on mortality met our predefined eligibility criteria, and our conclusion, incorporating careful grading of the certainty of evidence, reveals a less rosy picture. The bottom line demonstrates an important uncertainty whether ivermectin compared with placebo or standard of care reduces or increases mortality in moderately ill hospitalised patients (RR 0.60, 95% CI 0.14 to 2.51; two studies) and mildly ill outpatients (RR 0.33, 95% CI 0.01 to 8.05; two studies), due to serious risk of bias and imprecision.
It was excluded from future repurposed drug studies specifically because the dose from the few studies that have not been retracted about it is so uncertain.
Most studies and meta analysis since May show that it works about as well as a placebo.
https://ebm.bmj.com/content/early/2021/08/19/bmjebm-2021-111791.full